The Cannigma

MAY 16, 2025

The unstable legality of federal protections for medical cannabis, which solely come from an amendment to the DOJ and DEAs budget that has to pass every year, threatens our progress. and years of data proving the positive impacts that medical cannabis has on healthcare systems. ASA campaigns removed barriers for U.S.

Policy 92

Policy Advocacy Access Patients 92

Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy DEA Research and Development 52

Cannabis Law Report

JULY 12, 2019

31) The United States DEA has stated that small amounts of other cannabinoids will also occur in all cannabis extracts, even those that purport to be CBD only – unless synthesized de novo, CBD isolate will always contain small amounts of THC when extracted from a plant. 2002 Jun;42(8):993-1007. 32: United States DEA.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.

Recreational 52

Recreational DEA Data Cannabis 52

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2, 2002 , 116 Stat. 2, 2002 , 116 Stat. 2, 2002 , 116 Stat. 2(a), Oct. 21, 1998 , 112 Stat.

Banking 45

Banking Law Marijuana State Laws 45